CVE-2007-6763

CVE-2007-6763 is a high-severity vulnerability in Sas Sas Drug Development with a CVSS 3.x base score of 8.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-20.

Key facts

Description

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

Frequently asked questions

What is CVE-2007-6763?
SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.
How severe is CVE-2007-6763?
CVE-2007-6763 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2007-6763 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (67th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2007-6763?
CVE-2007-6763 affects Sas Sas Drug Development. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2007-6763?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2007-6763 published?
CVE-2007-6763 was published on 2019-07-31 and last updated on 2026-06-16.

References

Affected products (1)

Other CWE-20 (Improper Input Validation) vulnerabilities

Browse all CWE-20 (Improper Input Validation) vulnerabilities →